TransMedics Group, Inc. (TMDX) Price CAGR:-36.48%(TTM)
Over the latest trailing 12-month period, TransMedics Group, Inc. (TMDX)'s price cagr is -36.48%. The comparable SPY value is +25.01%. Year-to-date price return is -35.78%. Price CAGR uses adjusted close price history and excludes dividends.
Over longer horizons, TransMedics Group, Inc.'s Price CAGR averages 0.07% over 3 years and 21.48% over 5 years. The price CAGR (Compound Annual Growth Rate) shows how TransMedics Group, Inc.'s stock price has grown over various time periods. This measures pure price appreciation without including dividends.
TMDX Price CAGR Chart
TransMedics Group, Inc. (TMDX)
TMDX Quarterly Price (YoY)
Price growth vs the same quarter one year earlier, last 20 quarters.
TMDX Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 95.81 | 67.84 | -27.97 | -29.19% | -29.19% |
| 2025 | 127.99 | 95.81 | -32.18 | -25.14% | -25.14% |
| 2024 | 73.02 | 127.99 | +54.97 | +75.28% | +75.28% |
| 2023 | 22.00 | 73.02 | +51.02 | +231.91% | +231.91% |
| 2022 | 28.56 | 22.00 | -6.56 | -22.97% | -22.97% |
| 2021 | 16.59 | 28.56 | +11.97 | +72.15% | +72.15% |
| 2020 | 22.36 | 16.59 | -5.77 | -25.81% | -25.81% |
Quarterly Price: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 79 | -16.5% | -41.2% |
| Q1 2026 | 94 | -22.5% | +40.2% |
| Q4 2025 | 122 | +8.4% | +95.1% |
| Q3 2025 | 112 | -16.3% | -28.5% |
| Q2 2025 | 134 | +99.2% | -11.0% |
| Q1 2025 | 67 | +7.9% | -9.2% |
| Q4 2024 | 62 | -60.3% | -21.0% |
| Q3 2024 | 157 | +4.2% | +176.6% |
| Q2 2024 | 151 | +103.2% | +79.4% |
| Q1 2024 | 74 | -6.1% | -2.1% |
| Q4 2023 | 79 | +39.0% | +27.9% |
| Q3 2023 | 57 | -32.4% | +33.8% |
| Q2 2023 | 84 | +10.9% | +166.6% |
| Q1 2023 | 76 | +22.7% | +193.0% |
| Q4 2022 | 62 | +45.4% | +217.3% |
| Q3 2022 | 42 | +34.7% | +33.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein